v3.26.1
Segmented Information (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Total Research And Development Costs recovery $ (4,705) $ 9,959 $ 4,144 $ 30,298
General and administrative costs 2,032 4,500 2,385 10,266
General and administrative costs (2,032) (4,500) (2,385) (10,266)
Other income 1,087 1,216 3,352 4,014
Net Loss 7,824 (13,243) (3,177) (36,550)
Preclinical Studies [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Research and development costs 58 36 91 452
Clinical Trials [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Research and development costs 2,563 3,278 5,207 14,305
Personnel Costs [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Research and development costs 2,450 1,007 7,572 7,681
General and administrative costs 756 560 1,796 1,706
General and administrative costs (756) (560) (1,796) (1,706)
Non Cash Share Based Compensation [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Non-cash share-based compensations (recovery) (9,880) 2,607 (9,436) 4,704
[custom:NoncashSharebasedCompensationrecovery] (7,204) 1,718 (6,227) 3,124
Other Research And Development Costs [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Research and development costs 104 3,031 710 3,156
General and administrative costs 4,416 2,222 6,816 5,436
General and administrative costs $ (4,416) $ (2,222) $ (6,816) $ (5,436)